ReviewACS synthetic biology2015
Synthetic microbes as drug delivery systems.
Review in ACS synthetic biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed.
- Opportunities for artificial intelligence and synthetic biology in designing living drug delivery systems.Advanced drug delivery reviews · 2026Review
- Engineering the Gut Microbiome: Emerging Genome-Editing Strategies and Therapeutic Applications.Microorganisms · 2026Review
- Engineering non-pathogenic bacteria for auto-transporter-driven secretion of functional interferon.Gut microbes · 2025Article
- Microbial membrane vesicles and the intestinal epithelium: a crosstalk in health and disease.Archives of microbiology · 2025Review
- Learning to Navigate in Chemical Fields Without A Map at Low Reynolds Numbers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- AI-directed gene fusing prolongs the evolutionary half-life of synthetic gene circuits.Science advances · 2025Article
- Development of ultrasound-visualized tumor-targeting engineered bacteria for precise tumor therapy.Synthetic and systems biotechnology · 2025Article
- Engineering Saccharomyces cerevisiae for medical applications.Microbial cell factories · 2025Review
- Microbiome engineering: unlocking therapeutic potential in inflammatory bowel disease.Frontiers in microbiology · 2025Review
- Fabrication of cyborg bacterial cells as living cell-material hybrids using intracellular hydrogelation.Nature protocols · 2024Review
- Engineered bacterial therapeutics for detecting and treating CRC.Trends in cancer · 2024Review
- Long-Term Tumor-Targeting Effect ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Cas9-assisted biological containment of a genetically engineered human commensal bacterium and genetic elements.Nature communications · 2024Article
- The Current and Promising Oral Delivery Methods for Protein- and Peptide-Based Drugs.International journal of molecular sciences · 2024Review
- From competition to cure: the development of live biotherapeutic products for anticancer therapy in the iGEM competition.Frontiers in bioengineering and biotechnology · 2024Review
- The potential use of bacteria and bacterial derivatives as drug delivery systems for viral infection.Virology journal · 2023Review
- Microbial applications for sustainable space exploration beyond low Earth orbit.NPJ microgravity · 2023Review
- Complete Genome Sequence of an Escherichia coli Strain Isolated from Laboratory Mouse Stool for Use as a Chassis for Transgene Delivery to the Murine Microbiome.Microbiology resource announcements · 2023Article
- Recent advances in genetic tools for engineering probiotic lactic acid bacteria.Bioscience reports · 2023Article
- Engineered Cancer Targeting Microbes and Encapsulation Devices for Human Gut Microbiome Applications.Biochemistry · 2022Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Synthetic cell therapy is a field that has broad potential for future applications in human disease treatment. Next generation therapies will consist of engineered bacterial strains capable of diagnosing disease, producing and delivering therapeutics, and controlling their numbers to meet containment and safety concerns. A thorough understanding of the microbial ecology of the human body and the interaction of the microbes with the immune system will benefit the choice of an appropriate chassis that engrafts stably and interacts productively with the resident community in specific body niches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.